University of Pittsburgh Medical Center acquires biotechnology firm Rheogene Inc.

February 17, 2004

PITTSBURGH, Feb. 17 - The University of Pittsburgh Medical Center (UPMC) has acquired important gene regulation technology, thanks to a donation from specialty chemical company Rohm and Haas Co. The donation is the first of its kind for UPMC and includes intellectual property, equipment, compounds, biological materials, research and commercial agreements and licenses that have been consolidated into RheoGene Inc., a company based in suburban Philadelphia. The company formerly operated as RHeoGene LLC. Key business and technical personnel remain with the company at its Norristown, Pa. location.

RheoGene Inc. has developed technology to manage gene expression - a key component of gene-based therapies. The suburban Philadelphia-based company's gene regulation systems deliver precise control to develop new medical applications including cellular and gene therapies, genomics and enhanced protein expression. RheoGene's proprietary system uses a patented small-molecule mediator that can turn genes "on" or "off" as well as adjust the level of gene activity. In addition, the company is developing other pharmaceutical discovery agents used in research.

"The acquisition of the RheoGene technology furthers UPMC's commitment to be a guiding force in basic science research to improve health care and foster the growth of the biotechnology economy in the region," said Jeffrey Romoff, president of UPMC. "While it should represent a steadily increasing value to UPMC, we recognize that the real significance of this donation is the future benefit of its innovative clinical technologies to the people who matter most - the patients."

"We are excited to have UPMC as a strategic investor in RheoGene," said Tom Tillett, chief executive officer of RheoGene Inc. "This relationship will allow us to build upon the substantial investment Rohm and Haas has made in RheoGene's core technology that has allowed us to create a broad and deep intellectual property portfolio."

This unique strategic partnership between UPMC and RheoGene is a result of the collaborative efforts of Pennsylvania Gov. Edward Rendell; Dennis Yablonsky, commonwealth Secretary of the Department of Community and Economic Development (DCED) and former CEO of the Pittsburgh Life Sciences Greenhouse (PLSG); U.S. Sen. Rick Santorum, R-Pennsylvania; the Pittsburgh Tissue Engineering Initiative (PTEI); and the University of Pittsburgh's McGowan Institute for Regenerative Medicine.

A DCED Opportunity Grant made it possible for UPMC to retain a number of key RheoGene employees during the acquisition transition and to retain high-tech jobs in Pennsylvania. The company plans to open a clinical laboratory in Pittsburgh during 2004 to facilitate collaborations with UPMC, the University of Pittsburgh and the western Pennsylvania life-sciences community.

"RheoGene's technology and expertise has real strategic value for UPMC and the University of Pittsburgh and their investment in regenerative medicine research," said Alan J. Russell, Ph.D., director of the McGowan Institute and PTEI. "Technologies such as RheoGene's will be fundamental to realizing significant advances in areas such as personalized medicine where treatments will be individually tailored to provide each patient with the safest and most effective therapeutic options."

"UPMC is an ideal partner to foster the continued development of RheoGene's platform technology," said RheoGene CEO Tillett. "We now are well positioned to build on this work in wide-ranging applications such as pharmaceutical discovery, biotherapeutic protein production and agriculture, as well as to partner with UPMC and University of Pittsburgh researchers to further the development of therapeutic agents for patients."

RheoGene technologies have shown effectiveness in vitro and scientists are beginning the preclinical testing phase. Clinical trials in patients are still several years in the future, said Tillett.

"RheoGene's technology has important implications for advancing cell and gene therapies into the clinic," said Ronald B. Herberman, M.D., director of the University of Pittsburgh Cancer Institute and UPMC Cancer Centers. "This technology has the potential to link the functions of genes, proteins and complex cellular targets to discovery and development of new therapies for many diseases, including cancer."

RheoGene's RheoSwitch™ inducible gene expression technology systems allow gene expression to be dialed up and down in a manner analogous to a rheostat control on a light switch. The system pairs the company's proprietary RheoChem™ small-molecule inducers with proprietary RheoCept™ receptor proteins to precisely regulate gene expression.

"We look forward to many synergistic associations with leading researchers at UPMC and the University of Pittsburgh that will provide the company with a robust product pipeline as we go forward," said Tillett.

RheoGene's board of directors is led by UPMC treasurer C. Talbot Heppenstall Jr. and includes Elizabeth Concordia, senior vice president of UPMC's academic and community hospitals division and president of UPMC's Presbyterian and Shadyside hospitals; David Kalson, esquire, director, business group, Cohen & Grigsby, PC; and RheoGene's Tillett. Dr. Russell is the board's liaison with its scientific advisory group. Other members of the scientific advisory group are being recruited.

RheoGene product details
-end-
About RheoGene

RheoGene Inc. is the source of advanced products, applications and technologies that regulate gene expression for the development of safe and effective therapeutics. RheoGene Inc. delivers customized inducible gene expression products for pharmaceutical discovery, human therapeutics, biotherapeutics production and agriculture. RheoGene Inc. is a wholly owned subsidiary of RheoGene Holdings Inc. with operations in Norristown, Pa. For more information, visit http://www.rheogene.com.

About UPMC

UPMC is a non-profit, comprehensive academic health care system dedicated to providing patient care, educating the next generation of health care professionals and advancing biomedical knowledge through basic and clinical research. UPMC, which is affiliated with the University of Pittsburgh Schools of the Health Sciences, is the leading integrated delivery system for health care in western Pennsylvania and is one of the largest health systems in the United States. UPMC consists of a network of 19 tertiary, specialty and community hospitals and has more than 37,000 employees, making it the largest employer in western Pennsylvania. For more information, visit http://www.upmc.com.

CONTACT:
Michele D. Baum
Jane Duffield
PHONE: 412-647-3555
FAX: 412-624-3184
E-MAIL: BaumMD@upmc.edu
DuffieldDJ@upmc.edu

University of Pittsburgh Medical Center

Related Gene Therapy Articles from Brightsurf:

Risk of AAV mobilization in gene therapy
New data highlight safety concerns for the replication of recombinant adeno-associated viral (rAAV) vectors commonly used in gene therapy.

Discovery challenges the foundations of gene therapy
An article published today in Science Translational Medicine by scientists from Children's Medical Research Institute has challenged one of the foundations of the gene therapy field and will help to improve strategies for treating serious genetic disorders of the liver.

Gene therapy: Novel targets come into view
Retinitis pigmentosa is the most prevalent form of congenital blindness.

Gene therapy targets inner retina to combat blindness
Batten disease is a group of fatal, inherited lysosomal storage disorders that predominantly affect children.

New Human Gene Therapy editorial: Concern following gene therapy adverse events
Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM).

Restoring vision by gene therapy
Latest scientific findings give hope for people with incurable retinal degeneration.

Gene therapy/gene editing combo could offer hope for some genetic disorders
A hybrid approach that combines elements of gene therapy with gene editing converted an experimental model of a rare genetic disease into a milder form, significantly enhancing survival, shows a multi-institutional study led by the University of Pennsylvania and Children's National Hospital in Washington, D.C.

New technology allows control of gene therapy doses
Scientists at Scripps Research in Jupiter have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing.

Gene therapy: Development of new DNA transporters
Scientists at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed new delivery vehicles for future gene therapies.

Gene therapy promotes nerve regeneration
Researchers from the Netherlands Institute for Neuroscience and the Leiden University Medical Center have shown that treatment using gene therapy leads to a faster recovery after nerve damage.

Read More: Gene Therapy News and Gene Therapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.